Bank of New York Mellon Corp Sells 17,826 Shares of United Therapeutics Corporation $UTHR

Bank of New York Mellon Corp trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 5.1% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 333,629 shares of the biotechnology company’s stock after selling 17,826 shares during the quarter. Bank of New York Mellon Corp owned about 0.77% of United Therapeutics worth $162,561,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its holdings in United Therapeutics by 27.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,774 shares of the biotechnology company’s stock worth $53,975,000 after buying an additional 23,938 shares in the last quarter. Westpac Banking Corp bought a new stake in United Therapeutics in the 4th quarter worth about $719,000. Peak Retirement Planning Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $2,719,000. Natixis Advisors LLC grew its stake in shares of United Therapeutics by 0.5% during the 4th quarter. Natixis Advisors LLC now owns 11,768 shares of the biotechnology company’s stock valued at $5,734,000 after purchasing an additional 53 shares during the period. Finally, Florida Financial Advisors LLC grew its stake in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 28 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Bank of America boosted their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Trading Up 0.4%

Shares of NASDAQ:UTHR opened at $549.87 on Friday. The stock has a 50 day moving average of $568.23 and a 200 day moving average of $518.83. The company has a market cap of $23.34 billion, a PE ratio of 20.30, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.63 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 624,043 shares of company stock worth $351,649,680. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.